Post Job

Medimmune main competitors are Genentech, Illumina, and PacBio.

Competitor Summary. See how Medimmune compares to its main competitors:

  • Genentech has the most employees (13,638).
  • Employees at Genentech earn more than most of the competitors, with an average yearly salary of $97,473.
  • The oldest company is McNeil Consumer Healthcare, founded in 1879.
Work At Medimmune?
Share Your Experience

Medimmune vs competitors

CompanyFounding DateZippia ScoreHeadquarters# of LocationsRevenueEmployees
1987
4.7
Gaithersburg, MD1$422.2M6,030
1988
4.9
Tarrytown, NY7$12.2B9,123
1998
4.8
San Diego, CA5$4.6B7,800
1976
4.5
South San Francisco, CA5$166.9M13,638
1981
4.8
Cambridge, MA1$4.6B12,000
1947
4.4
Rockville, MD4$49.9M700
2010
4.8
Cambridge, MA2$19.3B2,500
1984
4.8
Bridgewater, NJ1$39.0M180
2004
4.7
Menlo Park, CA1$128.3M400
1998
4.8
Gaithersburg, MD12$1.1B1,834
1991
4.7
Westlake Village, CA2$10.0M233
1995
4.7
Austin, TX3$417.4M1,140
1995
4.5
Hopkinton, MA1$109.8M200
2006
4.1
Lexington, MA2$22.3M182
1967
4.2
Northwood, OH5$13.0M142
McNeil Consumer Healthcare
1879
4.3
Fort Washington, PA1$46.2M17
1987
4.5
Irvine, CA1$83.0M1,074
1992
4.0
Cambridge, MA1$10.0M350
1999
4.1
South Plainfield, NJ1$45.4M100
1915
4.8
Cincinnati, OH1$4.9B11,000
1963
4.7
Durham, NC1-6,828

Rate how well Medimmune differentiates itself from its competitors.

Zippia waving zebra

Medimmune salaries vs Competitors

Among Medimmune competitors, employees at Genentech earn the most with an average yearly salary of $97,473.

Compare Medimmune Salaries VS Competitors

CompanyAverage SalaryHourly SalarySalary Score
Medimmune
$78,540$37.76-
Regeneron
$85,589$41.15-
Illumina
$94,044$45.21-
Genentech
$97,473$46.86-
Sanofi Genzyme
$84,495$40.62-
BioReliance
$74,348$35.74-

Compare Medimmune Job Title Salaries VS Competitors

CompanyHighest SalaryHourly Salary
Medimmune
$80,942$38.91
Genentech
$101,944$49.01
Regeneron
$89,788$43.17
Emergent BioSolutions
$87,683$42.16
Sanofi Genzyme
$86,785$41.72
ImClone Systems LLC
$83,786$40.28
McNeil Consumer Healthcare
$82,728$39.77
Advanced Sterilization Products
$81,657$39.26
Ethicon
$79,398$38.17
Luminex
$78,255$37.62
Moderna
$77,559$37.29
Biomérieux
$76,942$36.99
Namsa
$75,697$36.39
Acambis
$74,829$35.98
Illumina
$72,961$35.08
T2 Biosystems
$72,677$34.94
BioReliance
$71,821$34.53
Caliper Life Sciences
$71,446$34.35
GENEWIZ
$71,285$34.27
MannKind
$70,634$33.96

Do you work at Medimmune?

Is Medimmune able to compete effectively with similar companies?

Medimmune Jobs

Medimmune demographics vs competitors

Compare Gender At Medimmune Vs Competitors

Job TitleMaleFemale
MannKind53%47%
Medimmune53%47%
Emergent BioSolutions56%44%
Luminex59%41%
Illumina62%38%
PacBio65%35%
Male
Female

Compare Race At Medimmune Vs Competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity Score
48%12%17%18%5%
9.9
60%11%16%9%4%
9.6
46%23%7%20%5%
9.7
48%23%11%14%3%
9.8
57%17%10%12%4%
9.0
42%20%5%27%5%
9.6

Medimmune And Similar Companies CEOs

CEOBio
Robert Kramer Sr.
Emergent BioSolutions

Robert Kramer is a President & Chief Executive Officer at EMERGENT BIOSOLUTIONS INC., Board Member at EMERGENT BIOSOLUTIONS INC., and Interim Exec VP:Services at EMERGENT BIOSOLUTIONS INC. and is based in Lansing, Michigan. He has experience at PHARMACIA CORP and has worked as Pres:Biosciences Div at EMERGENT BIOSOLUTIONS INC., Consultant at EMERGENT BIOSOLUTIONS INC., and President at Emergent Biodefense Ops Lansg. Robert works or has worked as Chief Executive Officer at Emergent Biodefense Operations. He studied at WESTERN KENTUCKY UNIVERSITY between 1980 and 1983 and Clemson University between 1975 and 1979.

Francis A. Desouza
Illumina

Francis Aurelio deSouza (born December 2, 1970) is an American entrepreneur and business executive. He is the president and chief executive officer (CEO) of Illumina and a member of the Board of Directors of The Walt Disney Company.

Nachum Shamir
Luminex

With a proven track record of bringing game-changing technologies to the market, Mr. Shamir joined Luminex Corporation as President, Chief Executive Officer, and Board Member in 2014. From 2006 to 2014, Mr. Shamir served as President and CEO of Given Imaging, a developer, manufacturer, and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract, which was acquired by Covidien PLC in early 2014. Mr. Shamir currently serves on the board of directors of Exalenz Bioscience Ltd. (TASE: EXEN). He has previously served as a Board Member at Scitex Corporation, Cogentix Medical (NASDAQ: CGNT), recently acquired by Laborie Medical Technologies, and invendo medical GmBH, now part of Ambu. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

Michael E. Castagna
MannKind

Michael Castagna is a Board Member at MANNKIND CORP and Chief Executive Officer at MANNKIND CORP and is based in Westlake Village, California. He has worked as Vice President & Head, Biopharmaceuticals North America at Sandoz; Director, Endocrinology Marketing at Healthcare Business of Merck; and VP/Global Head:Commercial at Amgen. Michael attended Massachusetts College of Pharmacy and Health Sciences between 2012 and 2014, The Wharton School between 2003 and 2005, and Philadelphia College of Pharmacy & Science.

Christian O. Henry
PacBio

John J. Sperzel
T2 Biosystems

CEO at T2 Biosystems | Board Member | Heart Transplant Recipient | Sepsis Survivor | Best Selling Author | Inspirational Speaker

Alexandre Mérieux
Biomérieux

Skip Wagner
BioReliance

Skip Wagner is a President and Chief Executive Officer at BioReliance and is based in College Station, Texas.

Benjamin Manico
Ethicon

Dynamic, results-oriented leader with a strong track record of performance in turnaround and high-paced organizations. Utilize keen analysis and insights and team approach to drive organizational improvements and implementation of best practices. Superior interpersonal skills, capable of resolving multiple and complex (sales, human resources, legal, financial, operational) issues and motivating staff to peak performance. Excellent political connections developed as selected member of Fiorello LaGuardia's mayoral team.

Alexander Hardy
Genentech

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Medimmune Competitors FAQs

Search for jobs